Electroanatomic Mapping System Research Articles

Impact of inter-lesion distance and first-pass isolation on outcomes of pulmonary venous isolation for paroxysmal atrial fibrillation.

Contiguity of ablation lesions is a critical determinant of success for paroxysmal atrial fibrillation (PAF) ablation. Evidence supports maintaining an inter-lesional distance (ILD) ≤ 6mm during pulmonary venous isolation (PVI). Meanwhile, first-pass isolation (FPI) on PVI outcome in follow-up was not deeply studied. The impact of ILD and FPI on PAF ablation outcomes was investigated. Consecutive PAF patients who underwent first-time antral PVI were recruited. Coordinates of ablation points were extracted from the electro-anatomical mapping system and analyzed using custom-developed software to determine the ILD. A gap is defined as ILD greater than 6mm. FPI was defined as the achievement of PVI by encircling the ipsilateral veins while simultaneously recording their electrical activity using a multipolar catheter. The primary endpoint was freedom from documented atrial arrhythmias including AF, atrial tachycardia (AT), or atrial flutter (AFL) lasting longer than 30s during follow-up. A total of 105 patients underwent first-time antral PVI. During 13.3 ± 0.6months of follow-up, atrial arrhythmias recurrence was noted in 22.9% of the patients. Atrial arrhythmia recurrence was significantly higher in patients with more gaps (> 2) (37.0% versus 11.9%, P < 0.01), and the number of gaps was an independent predictor of AF/AT/AFL recurrence. (Hazard ratio [HR] 1.20, 95% CI 1.03-1.40, P = 0.02). The group with FPI for at least one ipsilateral pair of PVs exhibited a decreased number of gaps (2.0 versus 7.0, P < 0.01) and demonstrated a significant correlation with a reduction of recurrence (HR 0.26, 95% CI 0.09-0.71, P = 0.01). Among 16 patients who underwent repeat ablation, the number of gaps during the index PVI was associated with PV reconnection (PVR) (P < 0.01). Gaps created during PVI are a modifiable determinant of AF/AT/AFL recurrence, and avoidance of gaps is crucial to improve clinical outcomes of PAF ablation. In addition, FPI exhibited a strong predictive capability for clinical success in patients with PAF.

ROLE OF CARDIOVASCULAR IMAGING IN CARDIO-ONCOLOGY: A LITERATURE REVIEW

Antitumor drugs are toxic to the cardiovascular system and directly affect cardiac function and anatomy. During the treatment of oncology, patients may experience complications in the form of asymptomatic myocardial dysfunction, severe heart failure, exacerbation of symptoms of coronary heart disease, thromboembolic complications, arterial and pulmonary hypertension, pericardial complications, valve defects and arrhythmias. A number of diagnostic tools are currently available to cardio-oncologists to detect cardiotoxicity, and the choice of imaging method depends on the availability of the specific diagnostic modality and its resolution. The main method for assessing the condition of the heart in cancer patients is echocardiography - a widely available method that enables to assess the structure of the heart and hemodynamics without exposing the patient to an additional dose of ionizing radiation. If imaging is insufficient, the recommended method for assessing cardiac structure and function is magnetic resonance imaging. Computed tomography of the chest, heart and coronary arteries is also used to diagnose complications of cancer treatment. In addition, nuclear medicine techniques, including gated radionuclide ventriculography, are also used to diagnose cardiotoxicity. Electroanatomical mapping systems combined with remote navigation are promising. Early detection of subclinical left ventricular myocardial dysfunction in cancer patients receiving potentially cardiotoxic drugs is advisable and aimed at secondary prophylaxis and prevention of mortality from cardiovascular diseases.

A real-time signal processing software package for the electrophysiology laboratory.

Real-time signal processing has to date been difficult to implement in the clinical electrophysiology laboratory. To date, no open access software solutions are available in electrophysiology (EP) laboratories to facilitate real-time intraprocedural signal analysis. We aimed to develop an open access, scalable Python plug-in to allow real-time signal processing during human EP procedures. A Python-based plug in for the widely available EnsiteX mapping system was developed. This plug-in utilized the LiveSync feature of the system to allow real-time signal analysis. An open access library was developed to allow end-users to implement real-time signal analysis using this platform, implemented in the Python programming language https://github.com/anand9176/WaveWatch5000Public. We have developed and demonstrated the feasibility of a readily scalable and open-access Python-based plug in to an electroanatomic mapping system (EnSiteX) to allow real-time processing and display of electrogram (EGM) based information for the procedural electrophysiologist to view intraprocedurally in the electrophysiology laboratory. The availability, to the clinician, of traditional and novel EGM-based metrics at the time of intervention, such as atrial fibrillation ablation, allows for key mechanistic insights into critical unresolved questions regarding arrhythmia mechanism.

Use of three-dimensional electroanatomic mapping for epicardial access: needle tracking, electrographic characteristics, and clinical application.

Pericardiocentesis is usually completed under fluoroscopy. The electroanatomic mapping (EAM) system allows visualizing puncture needle tip (NT) while displaying the electrogram recorded from NT, making it possible to obtain epicardial access (EA) independent of fluoroscopy. This study was designed to establish and validate a technique by which EA is obtained under guidance of three-dimensional (3D) EAM combined with NT electrogram. 3D shell of the heart was generated, and the NT was made trackable in the EAM system. Unipolar NT electrogram was continuously monitored. Penetration into pericardial sac was determined by an increase in NT potential amplitude and an injury current. A long guidewire of which the tip was also visible in the EAM system was advanced to confirm EA. Epicardial access was successfully obtained without complication in 13 pigs and 22 patients. In the animals, NT potential amplitude was 3.2 ± 1.0 mV when it was located in mediastinum, 5.2 ± 1.6 mV when in contact with fibrous pericardium, and 9.8 ± 2.8 mV after penetrating into pericardial sac (all P ≤ 0.001). In human subjects, it measured 1.54 ± 0.40 mV, 3.61 ± 1.08 mV, and 7.15 ± 2.88 mV, respectively (all P < 0.001). Fluoroscopy time decreased in every 4-5 cases (64 ± 15, 23 ± 17, and 0 s for animals 1-4, 5-8, 9-13, respectively, P = 0.01; 44 ± 23, 31 ± 18, 4±7 s for patients 1-7, 8-14, 15-22, respectively, P < 0.001). In five pigs and seven patients, EA was obtained without X-ray exposure. By tracking NT in the 3D EAM system and continuously monitoring the NT electrogram, it is feasible and safe to obtain EA with minimum or no fluoroscopic guidance.

Assessment of Esophageal Shifts during Catheter Ablation of Atrial Fibrillation Using Intracardiac Ultrasound Integrated with 3-Dimensional Electroanatomical Mapping System.

Purpose: Atrioesophageal fistula is one of the most feared complications of radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) as it is associated with high mortality. Determining the esophagus location during RFCA might reduce the risk of esophageal injury. The present study aims to evaluate the feasibility of using intracardiac echocardiography integrated into a 3-dimensional electroanatomical mapping system (ICE/3D EAM) for the assessment of esophageal position and shifts in response to ablation. Methods: We prospectively enrolled 20 patients that underwent RFCA of AF under conscious analgosedation. The virtual anatomy of the left atrium, the pulmonary vein (PV) ostia, and the esophagus was created with ICE/3D EAM. The esophageal positions were obtained at the beginning of the procedure and then after left and right PV isolation (PVI). Esophageal shifts were measured offline after the procedure using the tools available in the 3D EAM system. Results: Most esophagi moved away from the ablated PV ostia. After the left PVI, the median of the shifts was 2.8 mm (IQR 1.0-6.3). In 25% of patients, the esophagus shifted by >5.0 mm (max. 13.4 mm). After right PVI, the median of shifts was 2.0 mm (IQR 0.7-4.9). In 10% of patients, the esophageal shift was >5.0 mm (max. 7.8 mm). Conclusions: ICE/3D EAM enables the intraprocedural visualization of baseline esophageal position and its shifts after PVI. The shifts are variable, but they tend to be small and directed away from the ablation site. Repeated intraprocedural visualization of the esophagus may be needed to reduce the risk of esophageal injury.

First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation.

Pulsed field ablation (PFA) has significant advantages over conventional thermal ablation of atrial fibrillation (AF). This first-in-human, single-arm trial to treat paroxysmal AF (PAF) assessed the efficiency, safety, pulmonary vein isolation (PVI) durability and one-year clinical effectiveness of an 8 Fr, large-lattice, conformable single-shot PFA catheter together with a dedicated electroanatomical mapping system. After rendering the PV anatomy, the PFA catheter delivered monopolar, biphasic pulse trains (5-6 s per application; ∼4 applications per PV). Three waveforms were tested: PULSE1, PULSE2, and PULSE3. Follow-up included ECGs, Holters at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy endpoints were acute PVI and post-blanking atrial arrhythmia recurrence, respectively. Invasive remapping was conducted ∼75 days post-ablation. At three centres, PVI was performed by five operators in 85 patients using PULSE1 (n = 30), PULSE2 (n = 20), and PULSE3 (n = 35). Acute PVI was achieved in 100% of PVs using 3.9 ± 1.4 PFA applications per PV. Overall procedure, transpired ablation, PFA catheter dwell and fluoroscopy times were 56.5 ± 21.6, 10.0 ± 6.0, 19.1 ± 9.3, and 5.7 ± 3.9 min, respectively. No pre-defined primary safety events occurred. Upon remapping, PVI durability was 90% and 99% on a per-vein basis for the total and PULSE3 cohort, respectively. The Kaplan-Meier estimate of one-year freedom from atrial arrhythmias was 81.8% (95% CI 70.2-89.2%) for the total, and 100% (95% CI 80.6-100%) for the PULSE3 cohort. Pulmonary vein isolation (PVI) utilizing a conformable single-shot PFA catheter to treat PAF was efficient, safe, and effective, with durable lesions demonstrated upon remapping.

Ventricular tachycardia ablation after myocardial infarction guided by cardiac magnetic resonance/multidetector computed tomography image integration

Abstract INTRODUCTION The persistent challenge of ventricular tachycardia (VT) ablation lies in the elevated morbidity and mortality due to the underlying disease progression and the complexity of the arrhythmogenic substrate. As imaging methods are evolving, substrate-based VT ablation is moving closer to the realm of precision medicine. CASE PRESENTATION A 52-year-old patient with a history of hypertension, type II diabetes mellitus, hyperlipidemia, and stage IIIB chronic kidney disease was referred to our hospital for sustained monomorphic VT. Upon admission, the patient was hemodynamically stable. Laboratory results indicated mild anemia, moderate renal dysfunction, and normal myocardial enzymes. ECG during sinus rhythm showed widespread repolarization abnormalities in the apical and postero-lateral leads. Echocardiography revealed mild left ventricular dysfunction and coronary angiography confirmed significant lesions in multiple coronary arteries that were treated with drug-eluting stents (DES). Cardiac MRI showed relatively limited areas of old myocardial infarctions in the left circumflex artery and left anterior descending artery territories, therefore we decided to perform VT ablation. We used a Carto 3 Biosense Webster electro-anatomical mapping system (EAM) guided by fusion imaging (cardiac MRI and multidetector computed tomography - MDCT) with the aid of ADAS 3D software. The voltage map created during sinus rhythm, was concordant with the lesions identified on LGE-CMR. Radiofrequency (RF) catheter ablation targeted abnormal signals from the EAM, which were identified based on conduction channels (CCs) from the fusion imaging. There was complete VT non-inducibility at programmed ventricular stimulation (PVS). At the 3-month follow-up, echocardiography showed a slight improvement in LVEF and repeated PVS proved persistent ventricular arrhythmia non-inducibility. CONCLUSION Substrate-based VT ablation in structural heart disease has greatly improved by high-resolution substrate imaging with detailed anatomy, allowing successful personalized treatment. There is room for further improvement in the near future with the contribution of artificial intelligence, possibly with a more targeted and automated VT ablation.

Bipolar catheter ablation with dedicated radiofrequency system for highly refractory ventricular arrhythmia-Does the rate of success depend on arrhythmia origin?

Despite rapid technological progress, some arrhythmias are still resistant to standard unipolar ablation. These include arrhythmias arising from the base of the heart, cardiac crux, or epicardium. Bipolar radiofrequency ablation (B-RFA) may be useful in some cases, however, data on the efficacy of this approach in various arrhythmia localizations are scarce. The aim of this study was to assess the efficacy of B-RFA in patients with ventricular arrhythmias originating from various locations, occurring refractory to standard unipolar ablation approaches. An observational, single center study was conducted over a 30-month period. B-RFA were performed using dedicated radio frequency (RF) generator and electroanatomic mapping system. Twenty-four procedures, in 23 patients with a median (range) of 1 (1-2) previously failed unipolar ablation procedures, were included in the final analysis. There were 12 ablations of ventricular arrhythmias originating from interventricular septum with an acute success rate of 75%, and 12 from left ventricular (LV) summit with an acute success rate of 58%. The midterm success rate (medianinterquartile range follow-up of 205 days [188-338]) was 66% and 50%, respectively. B-RFA is a promising method of catheter ablation for refractory cardiac arrhythmias. A higher success rate was observed in ablation for difficult ventricular arrhythmias originating from interventricular septal region than LV summit.

The Fluoroless Future in Electrophysiology: A State-of-the-Art Review.

Fluoroscopy has always been the cornerstone imaging method of interventional cardiology procedures. However, radiation exposure is linked to an increased risk of malignancies and multiorgan diseases. The medical team is even more exposed to X-rays, and a higher incidence of malignancies was reported in this professional group. In the last years, X-ray exposure has increased rapidly, involving, above all, the medical team and young patients and forcing alternative fluoroless imaging methods. In cardiac electrophysiology (EP) and pacing, the advent of 3D electroanatomic mapping systems with dedicated catheters has allowed real-time, high-density reconstruction of both heart anatomy and electrical activity, significantly reducing the use of fluoroscopy. In addition, the diffusion of intracardiac echocardiography has provided high anatomical resolution of moving cardiac structures, providing intraprocedural guidance for more complex catheter ablation procedures. These methods have largely demonstrated safety and effectiveness, allowing for a dramatic reduction in X-ray delivery in most arrhythmias' ablations. However, some technical concerns, as well as higher costs, currently do not allow their spread out in EP labs and limit their use to only procedures that are considered highly complex and time-consuming and in young patients. In this review, we aim to update the current employment of fluoroless imaging in different EP procedures, focusing on its strengths and weaknesses.

Catheter ablation of supraventricular tachycardia and atrial flutter with no or minimal use of fluoroscopy: the initial experience of a single Bulgarian center

Introduction: Catheter ablation (CA) is an established therapy for most arrhythmias. Non-&amp;#64258; uoroscopic three-dimensional (3D) electroanatomic mapping systems allow ablation of supraventricular tachycardia (SVT) and atrial &amp;#64258; utter (AFL) with zero or near-zero &amp;#64258; uoroscopy (ZF/NZF). The current study aims to report our initial experience with ZF/NZF in SVT or AFL CA. Material and methods: We conducted a single-center prospective registry enrolling consecutive patients referred for CA of SVT or AFL. ZF/NZF CA was attempted in all patients using a commercially available 3D mapping&amp;nbsp;system. Fluoroscopy use was allowed at any point of the procedure. Procedural characteristics and long-term outcome were analyzed. The learning curve effect was also studied. Results: Sixty-three patients (age 53.5 &amp;plusmn; 14.1, 57% males) with SVT or AFL were enrolled. According to arrhythmia type typical AVNRT was diagnosed in 36 (57.1%) cases, right atrial &amp;#64258; utter in 25 (39.7%) cases, left-sided accessory pathway in 1 (1.6%) and focal right atrial tachycardia in 1 (1.6%) case. Three patients (4.8%) had two arrhythmia substrates. The procedure was performed with ZF in 49/63 cases (77.8%), while NZF was necessary in 14 (22.2%) patients with a &amp;#64258; uoroscopy time of 220 &amp;plusmn; 169 sec and a dose-area product of 7556 &amp;plusmn; 5886 mGy*cm2. Median procedural time was 88 (IQR 25-75 percentile 71.5-116) min with 22 (IQR 25-75 percentile 16-31) min of mapping time. Acute procedural success was accomplished in all patients with no periprocedural complications. Over a follow-up of 12 &amp;plusmn; 3 months, all patients remained arrhythmia-free. There was a learning curve effect with a signi&amp;#64257; cant reduction of procedural time (P = 0.025) and a signi&amp;#64257; cant difference (P = 0.019) in the rate of &amp;#64258; uoroscopy use among different periods of the study duration. Conclusion: ZF/NZF CA of SVT and AFL is associated with high ef&amp;#64257; cacy and safety. Entirely &amp;#64258; uoroless CA can be performed in the vast majority of patients. It is a feasible approach associated with a detectable learning curve effect.&amp;nbsp;

Outcomes of Focal Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia

BackgroundPulsed field ablation (PFA) is primarily used for treatment of atrial fibrillation as it provides better safety and efficacy. However, there are limited data available on the use of PFA for paroxysmal supraventricular tachycardia (PSVT). The study sought to describe the outcomes of PSVT ablation with a novel focal contact force (CF)-sensing PFA. MethodsIn this first-in-human pilot study, a focal CF-sensing PFA catheter was used for mapping and ablation navigated with an electroanatomic mapping system (EAMS). Pulsed field energy was delivered as biphasic/bipolar electrical pulse trains with 2000 V/delivery. CF was controlled from 2 g to 10 g during PFA. ResultsProcedural acute success was achieved without general anaesthesia or conscious sedation in all 10 patients, including 7 patients diagnosed with typical atrioventricular nodal re-entrant tachycardias and 3 patients with orthodromic reciprocating tachycardias. Successful target ablation time was 2.0 ± 0.5 seconds per patient, and the acute procedural success at the first single site was achieved in 5 patients. The mean skin-to-skin procedure time was 79.4 ± 15 minutes, PFA catheter dwell time was 50.1 ± 14 minutes, and fluoroscopy time was 6.2 ± 7 minutes. Maintenance of sinus rhythm was observed in all patients within 6-month follow-up. No serious adverse events occurred in any subjects during PFA or during the 6-month follow-up. ConclusionsA focal CF-sensing PFA catheter could effectively, rapidly, and safely ablate PSVT in conscious patients. Clinical Trial RegistrationNCT05770921

Initial clinical experience of atrial fibrillation ablation guided by a cryoballoon-compatible, magnetic-based circular catheter.

The circular catheter compatible with current cryoballoon system for atrial fibrillation (AF) ablation is exclusively sensed by impedance-based electro-anatomical mapping (EAM) system, limiting the accuracy of maps. We aim to investigate the feasibility and safety of a magnetic-based circular mapping catheter for AF ablation with cryoballoon. Nineteen consecutive patients who underwent pulmonary vein isolation (PVI) with cryoballoon for paroxysmal or persistent AF were included. EAMs of left atrium (LA) created by the LASSOSTAR™NAV catheter (Lassostar map) before and after PVI were compared to that generated by a high-density mapping catheter (Pentaray map) from different aspects including structural similarity, PV angle, LA posterior wall (LAPW) and low voltage areas (LVAs), and the amplitude of far field electrograms (FFEs) recorded by catheters. All patients had successful PVI without major complications. With similar mapping time and density, the LA volume calculated from the Pentaray map and Lassostar map were comparable. There were no significant differences in PV angle of all PVs and PW area (16.8 ± 3.2 vs. 17.1 ± 2.8, p = .516) between Pentaray map and Lassostar map. High structural similarity score was observed between two maps (0.783 in RAO/LAO view and 0.791 in PA view). Lassostar map detected lesser but not statistically significant extension of LVA (13.9% vs. 18.3%, p = .07). Amplitude of FFE was larger at the right superior PV on Lassostar map (0.21 ± 0.16 vs. 0.14 ± 0.11 mV, p = .041) compared to that on the Pentaray map. In our initial experience, PVI with cryoballoon and magnetic-based circular LASSOSTAR™NAV catheter was safe and effective based on the accurate LA geometry it created.

Integration of electro-anatomical maps in the planning phase of stereotactic arrhythmia radioablation for refractory ventricular tachycardia

Abstract Introduction Despite the efficacy of stereotactic arrhythmia radioablation (STAR) for the treatment of refractory ventricular tachycardia (VT), the planning phase to precisely delineate the arrhythmogenic substrate still suffers from limitations due to the incompatibility of data formats between 3D electro-anatomical mapping systems (EAM) and STAR planning software (CyberKnife). Purpose Within the STOPSTORM European consortium, we present a workflow to integrate all 3D EAM data (e.g. voltage, activation time, anatomical tags) into the STAR planning software using the open source software Slicer3D to improve targeting of the arrhythmogenic substrate. Method Two protocols were compared retrospectively. Protocol 1 (STAR gold-standard) comprised the manual contouring of the clinical target volume (CTV) on planning 4D-CAT SCAN drawn side-by-side using EAM (Carto3, Biosense Webster) screen-shots and diagnostic reports. Protocol 2 comprised semiautomatic segmentation of CTV on planning 4D-CAT SCAN using imported EAMs annotated with landmarks for VT target delimitation. The semiautomatic segmentation of CTVs included three steps: (1) semiautomatic segmentation of ventricular myocardium (VM), the blood-pool of the concerned ventricle and at least two additional cardiac cavities; (2) 3D alignment of EAM with the segmented cavities; and (3), 3D delineation of CTV identified as the transmural section of VM segment surrounding the EAM’s VT target delimited by the annotated landmarks. The volume overlap (Dice coefficient) and the absolute difference of the CTVs obtained with the two protocols were compared. Both measurements were expressed in percentage as follows: Dice coefficient 0% means no overlap and 100% complete overlap; absolute difference of volumes 0% means no difference and 100% means that one CTV was twice the size of the CTV generated by the other protocol. Results Both protocols were applied to four patients (65.5 ± 8.5 yo) with refractory VT successfully treated with STAR. Figure 1 shows an example (Patient 1) of the CTV contouring using the CARTO EAMs aligned with the CT images in Slicer3D. Figure 2 illustrates significant mismatch between the segmented CTVs of the two protocols. The median volume overlap of the CTVs was 44%, while the median volume absolute difference was 35%. Table 1 reports detailed results. Conclusion Our study reveals a high variability of CTV delineation for STAR using two different protocols. The intraprocedural assignment of anatomical landmarks for VT target delimitation on EAM appears promising to improve CTV delineation. Further research is needed to evaluate the correlation between STAR outcome and CTV delineation accuracy.

The zero fluoroscopic approach to avnrt ablation significantly reduces radiation without compromising safety, efficacy or procedure time compared to a conventional or minimal fluoroscopic approach

Abstract Introduction In 2020, we showed that ablation of AVNRT (induced under conventional fluroscopy) with a 3D electro-anatomical mapping system (EAMS) (minimal X-RAY group) significantly reduces radiation exposure without compromising safety, efficacy and procedure time compared to a procedure performed entirely under conventional fluoroscopy (X-RAY group). Purpose The objective of this study was to determine whether the direct use of EAMS in selected patients with a high probability of induction of AVNRT could reduce radiation exposure to near zero without compromising the safety, efficacy and duration of the procedure (EAMS group) Methods We compare the 136 patients in the X-RAY group, the 141 patients in the minimal X-RAY group with 39 patients included in the EAMS group (included between July 2020 and December 2022). All procedures were performed at a single centre in Belgium using the same 3D electroanatomical mapping system. In the EAMS group, fluoroscopy had to be used to guide catheter progression for only 5 patients. We compared radiation dose, acute success, complication rates and procedure duration. Results AVNRT induction was achieved in 38 of 39 patients in the EAMS group. Only one patient was not inducible, but the slow pathway ablation was performed on the basis of the arrythmic ECG recording which was highly suggestive of AVNRT; the success of the ablation could therefore not be validated acutely. Radiation dose in the EAMS group was significantly lower compared to the minimal X-RAY group and X-RAY group (8,5 vs 1179 and 2686 mgray.cm2, p &amp;lt;0,0001) and fluroscopic time was obviously shorter (0,02 vs 2,5 and 8,6 minutes, p&amp;lt;0,0001). Procedural time (74,3 vs 70 and 69 mon, p = NS) and success rate (97,5% vs 99 and 98%, p = NS) were not significantly different in the three groups. No serious complications were observed in any group. No minimal complication were reported in the zero-fluoroscopy group. Conclusion AVRNT catheter ablation using a zero-fluoroscopic approach with EAMS significantly reduces radiation exposure without compromising safety, efficacy or procedure time.

Need an endomyocardial biopsy? Call your electrophysiology team

Abstract Introduction With significant advances in targeted chemotherapeutic options for soft tissue tumours, obtaining a tissue diagnosis is more important than ever. Primary and secondary cardiac tumours are rare [1] and endomyocardial biopsy of these tumours has been sparsely reported [2-9]. Advanced tools in cardiac electrophysiology happen to lend themselves well to cardiac tumour biopsy. Our electrophysiology (EP) guided endomyocardial biopsy (EMB) service includes electrophysiologists, cardio-oncology specialists, cardiac imaging specialists, oncologists, and pathologists. For the last 9 years all targeted endomyocardial biopsies in our tertiary institution have been undertaken by our EP guided EMB service with extensive experience in electroanatomical mapping (EAM), visualisable sheaths and integrated intracardiac echography (ICE). We report the findings. Methods We performed a retrospective review of all cases referred to the EP guided endomyocardial biopsy service at our centre and identified those with attempts to biopsy a cardiac mass. We describe the incorporation of advanced electrophysiology techniques utilised by the service. Specifically, the use of intracardiac echocardiography integrated into an electro-anatomical mapping system and bioptome delivery via a visualisable, deflectable sheath. This allows for the real time 3D visualisation of the target mass, surrounding anatomy and position of the bioptome during biopsy. Results Of 38 patients who underwent targeted biopsy at our centre, a total of 8 patients (5 female; mean ± SD age 54 ± 21 years) were referred for cardiac tumour biopsy, undergoing a total of 9 procedures (mean ± SD duration 116 ± 21 mins). Table 1 details the patient’s pertinent history and underlying pathology, the tumour site, possible alternative biopsy sites, a summary of techniques and technologies utilised and the eventual diagnosis. In 100% of cases, tissue was sampled from the desired location, though in two patients the histological result was inconclusive due the retrieval of necrotic tissue or fibrotic tissue only. This translated into a definitive histopathological diagnosis in 75% of patients. One patient experienced a transient right bundle branch block during the procedure, in all others the procedures were uncomplicated. Image 1 exemplifies some of the cases with pre-procedure imaging results and intra-procedural views from both ICE and the EAM. Conclusion In this study, our approach to utilising the combination of intracardiac echocardiography integrated into an electro-anatomical mapping system and bioptome delivery via a visualisable, deflectable sheath appears safe, and provides unparalleled accuracy in endomyocardial sampling of cardiac tumours.Table 1Image 1

Transseptal puncture using electroanatomical mapping: a safe and cost-effective technique

Abstract Background The usual technique of transseptal puncture (TSP) uses fluoroscopy or intracardiac echocardiography. New techniques for oval fossa (OF) identification by electroanatomical mapping (EAM) have been described. However, the technique of direct visualization of the TSP needle added to the OF location by impedance mapping has not been investigated yet. Purpose To evaluate feasibility and safety of the TSP technique guided by the interatrial septum (IAS) impedance mapping and the TSP needle visualization using EAM system. Methods Consecutive patients who underwent ablation using TSP in July and August 2022 in our institute were included. The standard material for the procedure was used in addition to a temporary pacemaker (PM) connection cable. In all cases, the EAM system was CARTO 3 version 7 (Biosense Webster and a bipolar voltage map of right atrium and a impedance map of the IAS were constructed. The OF location was estimated based on the septal region with the lowest impedance and on traditional anatomical landmarks. Using a temporary PM cable connected to the proximal part of the TSP needle stylet, it was possible to visualize its distal portion on the 3D map used to guide the TSP. The entire process was simultaneously monitored under fluoroscopic visualization by an experienced professional. Results A total of 25 patients were included; mean age of 56 +/- 15 years, 16 (64%) were male. The most frequent procedure was atrial fibrillation ablation (86%); left atrium mean size of 40,26 +/- 5,2 mm. 9 patients (36%) were already submetted to a previous procedure using TSP. None of the patients had congenital heart disease. In all cases, the TSP was successfully performed and a correlation between the anatomical references and the lowest impedance region on the map was observed. There were no complications. Conclusion The technique of visualization of the TSP needle using EAM system added to IAS impedance mapping and use of anatomical markers seems to be a safe and cost-effective alternative for performing TSP. This technique could reduce ionizing radiation without need for additional materials.Impedance map and bipolar voltage mapLA (bipolar voltage map) and TSP orifice

Digital health in the EP lab: Initial experience using remote access and technical support for complex ablation procedures

Abstract Aims/Objectives Three-D electroanatomical mapping (EAM) systems are a prerequisite for treatment of complex arrhythmias. Until date, the EAM system is operated by qualified staff or a field technical engineer (FTE) from the control room. Novel technology allows for remote access (RA) of the EAM from anywhere in the world. RA increases the flexibility of the EP lab, reduces travel time for the FTE and overcomes hospital access limitations e. g. during the COVID-19 pandemic. We report on the safety and feasibility of remote operation of the EAM for complex ablation procedures. Methods RA mapping was achieved by combining the EAM software with an integrated audiovisual solution for remote support. Communication between the operator and the remote support was achieved using internet-based headphones in the RA group. The 3D EAM system was controlled exclusively from home office. In the conventional group (CG), EAM was exclusively controlled from the control room in the EP lab. Ablation procedures were performed as per institutional standard. Results We investigated 50 RA assisted consecutive electrophysiological procedures from 09/2022 to 02/2023 in our University Heart Center. We compared a group of patients undergoing ablation procedures with RA assistance (28/50 (56%) patients were male, median age: 66.5 yrs [IQR 56, 76], BMI: 25.2 kg/m2 [IQR 22, 30]) with a control group (31/50 (62%) male, median age: 66.5 yrs [IQR 54, 78], BMI 28.2 kg/m2 [IQR 24, 30], p &amp;gt; 0.05 for all). Ablation procedures were matched in both groups: 20 pulmonary vein isolations (3 paroxysmal, 17 persistent atrial fibrillation ), 4 cavotricuspidal isthmus ablations, 13 ablations of atrial tachycardia, 1 premature ventricular complex ablation, 3 of ventricular tachycardia, 2 AV reentry tachycardia and 7 AV-node reentry tachycardia cases. In the RA group, the 3D EAM system was controlled exclusively from home office in all patients. In one patient, the internet based headphone connection was instable. Therefore, the communication was established via a conventional smartphone. No other technical issue was noted. No switch to in house support was required. There were no major complications observed. Procedural data (total procedure time median 100 min [IQR 76, 120] vs. control group 86 min [IQR 60, 110], total fluoroscopy time (median 9.1 min [IQR 6, 13] vs. control group 8.7 min [IQR 5, 12], p &amp;gt; 0.05) were comparable to previous procedures without RA. Due to RA travel time could be reduced by 139 hr in total in comparison to the control group. Conclusions RA for EAM of any arrhythmia is feasible and safe in this single center study. Procedural data were comparable to previous procedures. In the future, this new solution might have a great impact on facilitating EP procedures.Table procedural data

Cardioneuroablation for symptomatic bradyarrhythmia: for whom it fails?

Abstract Background Cardioneuroablation (CNA) has been proposed as a new therapeutic approach in selected patients with symptomatic functional bradyarrhythmia including recurrent neurally-mediated syncope. Purpose In patients after CNA, we investigated the potential predictors of the recurrence of clinically significant bradyarrhythmia. Methods A retrospective study included 187 consecutive patients (age: 40±12 years; 57 % of males; predominant AV nodal phenotype of the disorder in 37 % of patients; post-atropine sinus rate acceleration by 72±31 %) who underwent their first CNA at our centre from 2014 to 2022 and were followed for the minimum of 3 months. Biatrial radiofrequency ablation was performed under general anaesthesia by irrigated-tip catheter at empirical sites of ganglionated plexi (GP) with the navigation by 3D electroanatomic mapping system and intracardiac echocardiography. Anterior right GP and posteromedial left GP were always targeted to modulate the innervation of both sinoatrial and atrioventricular nodes, irrespective of the clinical manifestation of the disease. The loss of responsiveness of both nodes to extracardiac vagus nerve stimulation (frequently bilateral) was the procedural endpoint. The association of baseline, procedural, and early follow-up characteristics with the recurrence of clinically significant bradyarrhythmia was analyzed. Results CNA with the procedural duration of 154±32 min and radiofrequency time of 14±7 min resulted acutely in sinus rate acceleration by 27±13 bpm, shortening of AH interval by 16±28 ms, an increase of Wenckebach point by 26±28 bpm, shortening of AV node effective refractory period by 114±128 ms, and sinus node recovery time by 462±867 ms. At the 3-month visit, the sinus rate was still significantly higher (83±14 bpm) than at baseline (61±13 bpm); with acceleration by 23±14 bpm. During a median follow up of 33 months (IQR: 18-48 months), recurrence of clinically significant bradyarrhythmia was documented in 18 (10 %) patients. Re-CNA was performed in 11 patients and was scheduled in 3 patients. In 6 (3 %) patients, a pacemaker was finally implanted. Compared to the rest of the population, patients with bradyarrhythmia recurrence were non-significantly younger (36±12 vs. 40±12 years, P=0.16) and had non-significantly less acceleration of sinus rate at the 3-month post-CNA visit (by 18±11 vs. 23±13 bpm, P=0.10) suggesting a trend to more pronounced reinnervation of the sinus node. Conclusion Long-term clinical efficacy of CNA is reasonably high. We did not identify practically useful predictors of CNA failure. This investigation was significantly limited by the low rate of clinical events.

Abstract 17847: Typical Right Atrial Flutter Ablation Using Subclavian Venous Access in Patients With Interrupted or Occluded Inferior Vena Cava

Introduction: Ablation for typical atrial flutter (AFL) traditionally involves vascular access from the femoral vein to facilitate advancing catheters through the Inferior Vena Cava (IVC) to the right atrium (RA). In patients with interrupted or occluded IVC, this procedure is challenging to perform. We report a case series of typical right AFL ablation using subclavian access in interrupted or occluded IVC. Cases: A 63-year-old female with typical AFL refractory to medical therapy was referred for radiofrequency ablation (RFA). She had a history of surgically corrected atrial septal defect at age 4 years with known IVC interruption draining into RA via an azygous venous extension. Another case involved a 41-year-old male with quadriplegia and typical AFL who underwent an attempted RFA from femoral access that was aborted due to massive thrombosis of IVC. Decision making: In both cases, two sheaths were placed into the left subclavian venous system using ultrasound guidance. A coronary sinus catheter and irrigated tip ablation catheter were advanced into the coronary sinus and RA respectively. Additionally, in the second case, an intracardiac echocardiography probe was inserted via separate venous access. Using the electroanatomic mapping system, entrainment and activation mapping confirmed a tricuspid isthmus-dependent AFL. RFA was performed using an open irrigated RFA catheter in a linear fashion resulting in the termination of the tachycardia to sinus rhythm. In the first case, ablation extended from the tricuspid annulus to the os of the hepatic vein at the 06:00 position. Post ablation, hemostasis was achieved using a suture-mediated closure device. At follow-up, both patients were asymptomatic without evidence of AFL on extended-duration cardiac monitoring. Conclusion: In patients with interrupted or occluded IVC, the subclavian veins can be accessed for mapping and ablation of typical AFL when traditional femoral venous access is challenging.

Methods and techniques for increasing the safety and efficacy of pulmonary vein isolation in patients with atrial fibrillation.

The most common type of sustained arrhythmia is atrial fibrillation (AF). Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation, which has emerged as the primary therapeutic strategy for atrial fibrillation patients. Unfortunately, about one-third of patients experience recurrent atrial arrhythmias after the procedure.